Guyer William sold $1.9M of CORT

Guyer William (Chief Development Officer) sold 20,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $93.13 ($93.11–$93.54, $1.86M total) across 2 trades on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guyer William
Published Jul 8, 2026, 11:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 11:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

An officer sold shares in an open-market transaction under a Rule 10b5-1 plan; this is generally not a strong standalone fundamental catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing date can create short-lived headline-driven noise, but the economic signal is diluted by the pre-arranged nature and the relatively small post-sale holding size (3,985 shares remaining).

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-08 for a sale executed 2026-07-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics (CORT).

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics insider sale: Chief Development Officer William Guyer sold about 20,000 shares at ~$93.13 on 2026-07-07 under a 10b5-1 plan.

Expected impact

Likely minimal, with any effect confined to short-term sentiment around the filing date.

Evidence & confidence

The transaction is an open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretability versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it unless paired with other negative catalysts.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • William Guyer

    Chief Development Officer who executed the sale.

  • Rule 10b5-1 plan

    Pre-arranged plan that reduces interpretive value of the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.